ArticleJournal of materials chemistry. B2025
Methylquinolinium-enhanced near-infrared hemicyanine dye for ratiometric NAD(P)H sensing in live cells
Article in Journal of materials chemistry. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We introduce a ratiometric sensor designed for sensitive and specific detection of NAD(P)H in living cells, tissues, and whole organisms. The sensor incorporates a methylquinolinium acceptor linked to a near-infrared hemicyanine dye, enabling a dual-emission ratiometric mechanism. Upon binding to NAD(P)H, the near-infrared emission at 684 nm decreases, while visible emission at 517 nm increases. This change results from the reduction of the methylquinolinium acceptor to an electron-giving 1-methyl-1,4-dihydroquinoline donor, which quenches the near-infrared emission through photon-induced electron transfer (PET). This ratiometric behavior ensures precise, live tracking of NAD(P)H levels while overcoming the systematic errors associated with intensity-based measurements. We validate the sensor's performance in several experimental settings. In HeLa cells, treatment with oxaliplatin, fludarabine, and glucose all induced a dose-dependent increase in NAD(P)H, as indicated by the rising visible emission and decreasing near-infrared emission. These treatments reflect changes in cellular NADH levels, demonstrating the sensor's ability to track metabolic shifts in response to pharmacological and nutritional stimuli. Additionally, larvae of the fruit fly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.